Literature DB >> 10651986

Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies.

A Birck1, V Ahrenkiel, J Zeuthen, K Hou-Jensen, P Guldberg.   

Abstract

The PTEN/MMAC1 gene on chromosome 10q23 encodes a lipid phosphatase with tumor-suppressive properties. Germline PTEN/MMAC1 mutations have been implicated as the predisposing factor in Cowden disease and other hamartoma syndromes, and somatic mutations and deletions have been identified in a wide range of human cancers, including 30-40% of metastatic melanoma cell lines. To study further the possible role of PTEN/MMAC1 in the pathogenesis and progression of malignant melanoma, we examined uncultured specimens from 16 primary and 61 metastatic tumors from 67 patients. Denaturing gradient gel electrophoresis was used to analyze systematically the coding region of PTEN/MMAC1 and revealed mutations in four of the metastatic samples (7%). Sequence analysis of the mutants identified a 1 bp frameshift insertion, a 2 bp frameshift deletion, an 11 bp frameshift deletion, and a single base substitution resulting in the generation of a premature stop codon. Analysis of two intragenic polymorphisms showed allelic loss in three of eight informative primary tumors (38%) and in 18 of 31 metastatic tumors (58%). One of the mutant cases showed allelic loss, suggesting that both PTEN/MMAC1 alleles were inactivated in this tumor. Altogether, these results suggest that mutation and deletion of PTEN/MMAC1 may contribute to the development and progression of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651986     DOI: 10.1046/j.1523-1747.2000.00877.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  37 in total

1.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 3.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 4.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

5.  p85 Associates with unphosphorylated PTEN and the PTEN-associated complex.

Authors:  Rosalia Rabinovsky; Panisa Pochanard; Chontelle McNear; Saskia M Brachmann; Jonathan S Duke-Cohan; Levi A Garraway; William R Sellers
Journal:  Mol Cell Biol       Date:  2009-07-27       Impact factor: 4.272

Review 6.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

7.  New horizons in melanoma treatment: targeting molecular pathways.

Authors:  Christopher W M Soon; Alain P Algazi; Edward N Cha; Adil I Daud
Journal:  Ochsner J       Date:  2010

8.  DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR.

Authors:  Goran Micevic; Viswanathan Muthusamy; William Damsky; Nicholas Theodosakis; Xiaoni Liu; Katrina Meeth; Emily Wingrove; Manjula Santhanakrishnan; Marcus Bosenberg
Journal:  Cell Rep       Date:  2016-02-25       Impact factor: 9.423

9.  Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.

Authors:  C Nogueira; K-H Kim; H Sung; K H T Paraiso; J-H Dannenberg; M Bosenberg; L Chin; M Kim
Journal:  Oncogene       Date:  2010-08-16       Impact factor: 9.867

10.  UVB-induced ERK/AKT-dependent PTEN suppression promotes survival of epidermal keratinocytes.

Authors:  M Ming; W Han; J Maddox; K Soltani; C R Shea; D M Freeman; Y-Y He
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.